Strong Buy · 80/100Jul 29, 2:34 PM EDT
Ionis Targets $3B+ Peak Sales for TRYNGOLZA, Guides $875M-$900M in 2026 Revenue
IONS
Ionis Pharmaceuticals (IONS) provided a 2026 revenue outlook of $875M-$900M during its Q2 earnings call, driven by the launch of TRYNGOLZA. Management highlighted the drug's potential to exceed $3 billion in peak sales, positioning the company for significant…
- ▹Strong revenue guidance and peak sales target for TRYNGOLZA indicate commercial traction
- ▹Platform company with multiple pipeline assets and no recent regulatory negatives
Watchlist · 75/100Jul 29, 4:14 AM EDT
AbbVie's Rinvoq Secures EU Approval as First Systemic Therapy for Vitiligo
ABBVABBV:CA
AbbVie announced that the European Commission has approved Rinvoq (upadacitinib) for treating non-segmental vitiligo in patients aged 12 and older who are candidates for systemic therapy. This marks the first systemic treatment for vitiligo in the EU, expandin…
- ▹First-in-class systemic treatment for vitiligo in EU, strong regulatory win
- ▹AbbVie's established commercial infrastructure and Rinvoq's growing label
Watchlist · 70/100Jul 29, 10:22 AM EDT
Amgen's Repatha Gets EU Nod for Cardiovascular Risk Reduction in High-Risk Patients
AMGN
Amgen (AMGN) announced that the EMA's CHMP issued a positive opinion for Repatha (evolocumab) to reduce cardiovascular risk in adults with high-risk atherosclerotic cardiovascular disease by lowering LDL-C levels. This recommendation brings the drug closer to…
- ▹Positive CHMP opinion supports regulatory approval in EU
- ▹Repatha is a commercialized product with growing demand
Watchlist · 65/100Jul 29, 3:55 PM EDT
Biogen Targets $12-$13 Non-GAAP EPS by 2026, Sees Strong Growth for SYFOVRE and EMPAVELI Through 2028
BIIB
Biogen (BIIB) provided long-term guidance during its Q2 2026 earnings call, projecting non-GAAP EPS of $12 to $13 by 2026 and expecting mid- to high teens growth for SYFOVRE and EMPAVELI through at least 2028. The company noted that its growth portfolio now su…
- ▹SYFOVRE and EMPAVELI growth guidance supports commercial strength
- ▹Non-GAAP EPS guidance provides financial visibility but lacks regulatory catalyst
Watchlist · 65/100Jul 29, 1:47 PM EDT
Allogene Surges on FDA Fast Track and RMAT Designations for CAR T Therapy
ALLO
Allogene Therapeutics (ALLO) shares rose after the FDA granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for its allogeneic CAR T cell therapy, cema-cel. These designations could accelerate development and regulatory review, pot…
- ▹FDA Fast Track and RMAT designations provide regulatory acceleration and potential for expedited approval.
- ▹Allogeneic CAR T platform offers technological differentiation but single-asset focus limits upside.
Watchlist · 65/100Jul 28, 3:04 PM EDT
Alkermes Guides Q3 2026 Revenue to $450M-$470M as CEO Handover and Key Orexin Data Loom
ALKS
Alkermes (ALKS) provided Q3 2026 revenue guidance of $450M-$470M, with CEO Richard Pops set to step down next week. The company highlighted its lead in orexin development, positioning alixorexton as the only orexin 2 receptor agonist in late-stage trials, with…
- ▹Orexin program leadership and upcoming readouts provide technology upside
- ▹Commercial revenue guidance supports commercial strength, but CEO transition and single-asset risk cap narrative
Neutral · 63/100Jul 29, 10:24 AM EDT
AbCellera Partners with Vertex to Develop T-Cell Engagers for Autoimmune Diseases
ABCLVRTX
AbCellera (ABCL) announced a collaboration with Vertex Pharmaceuticals (VRTX) to discover and conduct early research on T-cell engagers targeting autoimmune diseases. The deal leverages AbCellera's T-cell engager platform, potentially expanding its pipeline an…
- ▹BD deal with Vertex validates platform tech
- ▹Early-stage discovery; no near-term revenue or regulatory catalyst
Neutral · 62/100Jul 29, 10:56 PM EDT
Viking Targets Q4 2026 for Oral VK2735 Phase III Start; VANQUISH Program on Track
VKTX
Viking Therapeutics (VKTX) expects to initiate Phase III trials for its oral VK2735 in Q4 2026, as the injectable VANQUISH program remains on schedule. Both VANQUISH-1 (obesity) and VANQUISH-2 (obesity with type 2 diabetes) are fully enrolled and advancing, wi…
- ▹Phase III fully enrolled and on track for injectable VK2735; oral version Phase III start expected Q4 2026
- ▹Single-asset company with no commercial revenue; manufacturing capacity unknown
Neutral · 57/100Jul 29, 6:14 PM EDT
Amarin Sees 2026 Cash Flow Boost on 48% VASCEPA Market Share, 69% European Sales Surge
AMRN
Amarin (AMRN) reported that VASCEPA's U.S. market share reached 48% and European demand rose 69% in Q2 2026, driving the company to expect positive full-year 2026 cash flow. The results mark a key inflection point for Amarin's dual U.S.-partnered international…
- ▹VASCEPA market share growth and Europe demand up 69% show commercial traction
- ▹Single-asset company with no new pipeline catalysts limits upside
Neutral · 52/100Jul 29, 7:14 PM EDT
Anika Therapeutics Boosts Revenue Outlook, Targets 13%-17% Adjusted EBITDA Margin by 2026
ANIK
Anika Therapeutics (ANIK) raised its revenue growth outlook to 5%-10% and projects an adjusted EBITDA margin of 13%-17% by 2026, driven by commercial channel growth and gross margin expansion. The company reported its highest adjusted EBITDA since 2020 in Q2,…
- ▹Revenue growth and margin expansion indicate commercial traction, but single-asset risk and lack of regulatory catalysts cap upside.
Neutral · 52/100Jul 29, 4:47 PM EDT
MiMedx to Acquire Sanara MedTech in $35/Share Deal
SMTIMDXG
MiMedx (MDXG) has agreed to acquire Sanara MedTech (SMTI) for $35 per share, consisting of $33 in cash and 0.4735 shares of MiMedx stock. The deal values Sanara at a premium and expands MiMedx's wound care portfolio, potentially driving synergies and revenue g…
- ▹M&A deal with cash and stock, moderate commercial overlap
- ▹No major regulatory or technology catalysts, single-asset risk reduced but not eliminated
Neutral · 52/100Jul 29, 2:54 PM EDT
UniQure Plans AMT-130 BLA Filing This Quarter, Cash Runway Extended to 2030
QURE
UniQure announced plans to file a Biologics License Application (BLA) for its gene therapy AMT-130 this quarter, following regulatory guidance from the FDA and MHRA. The company also reported a cash runway extending into 2030, providing financial stability thr…
- ▹FDA guidance for AMT-130 BLA this quarter supports regulatory path, but single-asset risk remains high.
- ▹Cash runway into 2030 reduces dilution risk, but no commercial revenue or partnership yet.
High Risk · 42/100Jul 29, 4:14 PM EDT
Inventiva Cash Runway Extended to Q2 2027
IVA
Inventiva reported €166.1M in cash and short-term deposits as of June 30, with additional proceeds from recent financing. The company expects this to fund operations into Q2 2027, providing a long cash runway for its clinical programs.
- ▹Cash runway extended to Q2 2027 reduces near-term dilution risk
- ▹Single-asset clinical-stage biotech with no regulatory or commercial catalysts
High Risk · 42/100Jul 28, 1:55 PM EDT
ProMIS Surges on Interim Alzheimer's Trial Results; Guggenheim Raises Price Target
PMNBIIBLLY
ProMIS Neurosciences (PMN) shares rose after releasing six-month blinded interim data from a Phase 1 trial of its lead Alzheimer's therapy, PMN310. The positive early-stage results prompted Guggenheim to raise its price target on the stock, signaling potential…
- ▹Single-asset micro-cap with early-stage data; no regulatory path clarity
- ▹Positive interim data but limited commercial validation
High Risk · 37/100Jul 29, 9:12 AM EDT
Tevogen Bio Rebrands as Tevogen Inc., Signaling Healthcare Expansion
TVGN
Tevogen Bio Holdings (TVGN) is changing its name to Tevogen Inc., effective July 30, 2026, following board approval. The rebranding reflects the company's evolution into a broader healthcare enterprise, while its Nasdaq tickers (TVGN and TVGNW) remain unchange…
- ▹Name change only, no clinical or regulatory progress
- ▹Single-asset micro-cap with no revenue or pipeline depth
High Risk · 32/100Jul 29, 4:10 PM EDT
INOVIO stock slides on plans for new public offering of common stock and warrants
INO
INOVIO Pharmaceuticals announced a proposed underwritten public offering of common stock and warrants, which typically dilutes existing shareholders. The stock fell on the news, reflecting investor concerns about dilution. The offering includes a 30-day option…
- ▹Dilution risk from public offering; single-asset company with no approved products; negative narrative due to stock decline.
High Risk · 27/100Jul 28, 4:18 PM EDT
MapLight Therapeutics Bounces 23% After Devastating 73% Plunge on Mixed Schizophrenia Data
MPLT
MapLight Therapeutics (MPLT) shares rebounded 23% on Wednesday, recovering some losses after a 73% crash on Monday. The collapse followed mixed Phase 2 results for its lead schizophrenia drug, raising uncertainty about the drug's path to approval.
- ▹Mixed Phase 2 results for lead candidate caused 73% drop; partial recovery is not a positive catalyst.
- ▹Single-asset clinical-stage company with no approved products, high risk of further decline.
High Risk · 22/100Jul 29, 5:34 PM EDT
Capricor's Duchenne Therapy Deramiocel Fails to Win FDA Panel Support
CAPR
An FDA advisory panel voted against endorsing Capricor Therapeutics' deramiocel for Duchenne muscular dystrophy cardiomyopathy, citing insufficient evidence of efficacy. The negative vote could complicate the drug's approval path, potentially impacting CAPR's…
- ▹FDA advisory panel failed to endorse, severe regulatory setback
- ▹Single-asset micro-cap with negative FDA feedback